Skip to main content
SpringerLink
Log in

Denosumab not cost effective for osteoporosis in Australia

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Australian dollars

Reference

  • Karnon J, et al. What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost Effectiveness and Resource Allocation 14: No. 11, 13 Oct 2016. Available from: URL: http://dx.doi.org/10.1186/s12962-016-0060-5

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Denosumab not cost effective for osteoporosis in Australia. PharmacoEcon Outcomes News 765, 13 (2016). https://doi.org/10.1007/s40274-016-3498-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3498-y

Search

Navigation